Danqing Kong

6PUBLICATIONS
6CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Traditional Chinese medicine and treatmentsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 02, 2026
Long-Term Follow-Up of Chidamide With Chemotherapy in Untreated Peripheral T-Cell Lymphoma: One Single Center Real-World Study in China.

|Oct 05, 2024
Real-world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag.

Hong Tian, Lu Zhou, Jia-Wen Dai

|Sep 09, 2022
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.

Jie Yin, Hong Tian, Danqing Kong

|Jul 20, 2022
Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy.

Changju Qu, Nana Ping, Danqing Kong

|Oct 20, 2021
Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.

Danqing Kong, Yun Li, Chengcheng Fu

|Jul 24, 2020
CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph+ mixed phenotype acute leukaemia with minimal residual disease.

Danqing Kong, Changju Qu, Haiping Dai

Pageof 1

Frequent Collaborators

2 joint publications

Jie Yin

2 joint publications

Zhengming Jin

1 joint publications

Hong Tian

1 joint publications

Lu Zhou